Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel Free EVLO Stock Alerts

Evelo Biosciences (EVLO) Competitors

Evelo Biosciences logo
Compare

EVLO vs. PXMD, GNCA, ARDS, GNCAQ, and ORGS

Should you buy Evelo Biosciences stock or one of its competitors? MarketBeat compares Evelo Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Evelo Biosciences include PaxMedica (PXMD), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Genocea Biosciences (GNCAQ), and Orgenesis (ORGS). These companies are all part of the "pharmaceutical products" industry.

How does Evelo Biosciences compare to PaxMedica?

Evelo Biosciences (NASDAQ:EVLO) and PaxMedica (NASDAQ:PXMD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, risk and media sentiment.

Evelo Biosciences' return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
Evelo BiosciencesN/A N/A N/A
PaxMedica N/A -3,167.89%-560.35%

0.3% of Evelo Biosciences shares are held by institutional investors. Comparatively, 4.9% of PaxMedica shares are held by institutional investors. 1.0% of Evelo Biosciences shares are held by insiders. Comparatively, 1.0% of PaxMedica shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Evelo Biosciences has a beta of 1.78, indicating that its share price is 78% more volatile than the broader market. Comparatively, PaxMedica has a beta of -0.99, indicating that its share price is 199% less volatile than the broader market.

PaxMedica is trading at a lower price-to-earnings ratio than Evelo Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evelo BiosciencesN/AN/A-$114.53M-$4.21N/A
PaxMedicaN/AN/A-$18.29M-$6.09N/A

In the previous week, Evelo Biosciences' average media sentiment score of 0.00 equaled PaxMedica'saverage media sentiment score.

Company Overall Sentiment
Evelo Biosciences Neutral
PaxMedica Neutral

Summary

Evelo Biosciences beats PaxMedica on 6 of the 8 factors compared between the two stocks.

How does Evelo Biosciences compare to Genocea Biosciences?

Evelo Biosciences (NASDAQ:EVLO) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, media sentiment, earnings and analyst recommendations.

Evelo Biosciences' return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Evelo BiosciencesN/A N/A N/A
Genocea Biosciences N/A -182.88%-62.76%

0.3% of Evelo Biosciences shares are held by institutional investors. Comparatively, 0.6% of Genocea Biosciences shares are held by institutional investors. 1.0% of Evelo Biosciences shares are held by insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Genocea Biosciences has higher revenue and earnings than Evelo Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evelo BiosciencesN/AN/A-$114.53M-$4.21N/A
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A

Evelo Biosciences has a beta of 1.78, meaning that its stock price is 78% more volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 1.61, meaning that its stock price is 61% more volatile than the broader market.

In the previous week, Evelo Biosciences' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company Overall Sentiment
Evelo Biosciences Neutral
Genocea Biosciences Neutral

Summary

Genocea Biosciences beats Evelo Biosciences on 5 of the 9 factors compared between the two stocks.

How does Evelo Biosciences compare to Aridis Pharmaceuticals?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aridis PharmaceuticalsN/AN/A-$30.37M$0.31N/A
Evelo BiosciencesN/AN/A-$114.53M-$4.21N/A

In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Evelo Biosciences'average media sentiment score.

Company Overall Sentiment
Aridis Pharmaceuticals Neutral
Evelo Biosciences Neutral

Aridis Pharmaceuticals has a beta of 47.59, meaning that its stock price is 4,659% more volatile than the broader market. Comparatively, Evelo Biosciences has a beta of 1.78, meaning that its stock price is 78% more volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Aridis PharmaceuticalsN/A N/A N/A
Evelo Biosciences N/A N/A N/A

9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.3% of Evelo Biosciences shares are owned by institutional investors. 5.5% of Aridis Pharmaceuticals shares are owned by company insiders. Comparatively, 1.0% of Evelo Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Aridis Pharmaceuticals beats Evelo Biosciences on 6 of the 6 factors compared between the two stocks.

How does Evelo Biosciences compare to Genocea Biosciences?

Genocea Biosciences (NASDAQ:GNCAQ) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A N/A N/A
Evelo Biosciences N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea BiosciencesN/AN/AN/AN/AN/A
Evelo BiosciencesN/AN/A-$114.53M-$4.21N/A

Genocea Biosciences has a beta of 2.44, indicating that its stock price is 144% more volatile than the broader market. Comparatively, Evelo Biosciences has a beta of 1.78, indicating that its stock price is 78% more volatile than the broader market.

0.3% of Evelo Biosciences shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by insiders. Comparatively, 1.0% of Evelo Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Evelo Biosciences'average media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
Evelo Biosciences Neutral

Summary

Genocea Biosciences and Evelo Biosciences tied by winning 2 of the 4 factors compared between the two stocks.

How does Evelo Biosciences compare to Orgenesis?

Evelo Biosciences (NASDAQ:EVLO) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

Orgenesis has higher revenue and earnings than Evelo Biosciences. Orgenesis is trading at a lower price-to-earnings ratio than Evelo Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evelo BiosciencesN/AN/A-$114.53M-$4.21N/A
Orgenesis$662K3.12-$55.36M-$11.51N/A

Evelo Biosciences has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%.

Company Net Margins Return on Equity Return on Assets
Evelo BiosciencesN/A N/A N/A
Orgenesis -3,827.81%N/A -130.18%

0.3% of Evelo Biosciences shares are held by institutional investors. Comparatively, 22.6% of Orgenesis shares are held by institutional investors. 1.0% of Evelo Biosciences shares are held by company insiders. Comparatively, 1.9% of Orgenesis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Evelo Biosciences has a beta of 1.78, meaning that its stock price is 78% more volatile than the broader market. Comparatively, Orgenesis has a beta of 3.14, meaning that its stock price is 214% more volatile than the broader market.

In the previous week, Evelo Biosciences' average media sentiment score of 0.00 equaled Orgenesis'average media sentiment score.

Company Overall Sentiment
Evelo Biosciences Neutral
Orgenesis Neutral

Summary

Orgenesis beats Evelo Biosciences on 5 of the 9 factors compared between the two stocks.

Get Evelo Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for EVLO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EVLO vs. The Competition

Export
MetricEvelo BiosciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$2K$975.11M$6.87B$12.26B
Dividend YieldN/A4.84%2.67%9.79%
P/E Ratio0.001.5327.1423.64
Price / SalesN/A105.75517.0688.99
Price / CashN/A20.0650.5459.64
Price / BookN/A8.4710.286.07
Net Income-$114.53M-$2.70M$3.60B$331.99M

Evelo Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EVLO
Evelo Biosciences
N/AN/AN/AN/A$2KN/AN/A120
PXMD
PaxMedica
N/A$0.00
flat		N/A+400.0%$8KN/AN/A2
GNCA
Genocea Biosciences
N/AN/AN/AN/A$6K$1.91MN/A70
ARDS
Aridis Pharmaceuticals
N/AN/AN/AN/A$5KN/A0.0030
GNCAQ
Genocea Biosciences
N/AN/AN/AN/A$5KN/AN/A70

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:EVLO) was last updated on 7/25/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Three oil giants buried the same discovery for 50 years
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel